PPARGC1A and Hepatic fibrosis: The increased hepatic levels of Ppargc1a in TKO-HFD mice may counteract the effect of IL-1β through increased anti-inflammatory signaling [31], suggesting that TKO mice may also be protected against hepatic fibrosis.